1. Tanwar KS, Sawant VV, Rawat D, Dubey V, Shaikh AW, Dwivedi P, Dev I, Choudhury S, Agrawal A (2026). Radiolabeling and physicochemical characterization of terbium-161 DOTATATE. Nuclear Medicine Communications.

2. Punde R, Kshirsagar D, Shinde P, Darekar K, Chaudhari L, Laskar S (2026). Evaluation of revised TRS398 dosimetry protocol for pencil beam scanning proton therapy systems. Biomedical Physics & Engineering Express. 12(4).

3. Sridhar K, Moiyadi A, Balasubramaniam A, Panikar D, Muzumdar D (2026). Pre surgical evaluation of high grade gliomas in the Asia Pacific region: a pragmatic resource stratified framework. Journal of Clinical Neuroscience. 152:112188.

4. Saha P, Malu P, Joshi P, Hole A, Chaturvedi P, Vahanwala S, Krishna CM (2026). Raman spectroscopy of biofluids: fusion strategies for detecting oral potentially malignant disorders and oral Cancers. Applied Spectroscopy.

5. Gala RM, Prasad M, Srinivasan S, Gollamudi VRM, Dhamne C, Moulik NR, Parambil B, Chichra A, Narula G, Chinnaswamy G (2026). Nutritional status at diagnosis and follow-up and its impact on short-term clinical outcome in children with cancer: a real-world report from India. Ecancermedicalscience. 20:2137.

6. Ambekar T, Oak A, Kannusamy S, Cheulkar S, John RR, Chavan S, Mendhe S, Kadam S, Lade M, Balasubramanium G, Desouza A, Saklani A, Dikshit R, Chaturvedi P, Gupta S (2026). A hospital-based study of survival in colon cancer patients of Tata Memorial Hospital (Mumbai). Ecancermedicalscience. 20:2123.

7. Coupland SE, Rao A, Jonigk D, Bülow R, Chetty R, Rane SU, Dave S, Naresh KN (2026) . Promise and pragmatism of AI in global-scale digital pathology: pan-cancer approaches for clinical practice. Journal of Clinical Pathology.

8. Jobanputra K, Dhanawat A, Prakash G, Arora A, Dey S, Pawar A, Jadhav B, Menon N, Shah M, Pal M, Bakshi G, Murthy V, Maitre P, Popat P, Sable N, Ringe-Katdare A, Agrawal A, Menon S, Noronha V, Prabhash K, Joshi A (2026). Prognostic Reclassification and Survival Outcomes in Intermediate-Risk and Poor-Risk Nonseminomatous Germ Cell Tumors: Single-Institution Experience From Western India. JCO Global Oncology. 12(7):e2500695.

9. Mandal G, Biswas S, Anadon CM, Tamuli B, Chaurio RA, Lopez-Bailon LU, Plappert N, Carrion-Estrada D, Mine JA, Lai C-H, Moreno AP, Johnson J, Moran-Segura CM, Fang B, Marchion D, Chaudhary N, Terry KL, Sasamoto N, Townsend MK, O’Brien J, Antonia SJ, Tworoger SS, Yu X, Rodriguez PC, Conejo-Garcia JR (2026). Isotype-switched antibodies originating from tertiary lymphoid structures can antagonize ovarian cancer progression,iScience. 29(8):116757

Thesis
Girish Chandra Panigrahi. 2026. To evaluate the druggability of mitochondrial redox for targeting therapy resistant non-small cell lung cancer using mitocurcumin (LIFE09201904005) (Guide: Dr Vikram Gota)

SUPERFAMILY is a database of structural and functional annotation for all proteins and genomes.

Mansouri S, Hesami G, Ambikan A, Karger A, Klatt S, Neogi U, Kurakula KB, Aliraj B, Miller A, Petrova B, Sanda M, Sirait-Fischer E, Guenther S, Kuenne C, Ruppert C, Alkoudmani I, Gattenlöhner S, Zukunft S, Fleming I, Haschemi A, Stiewe T, Grimminger F, Reck M, Weigert A, Seeger W, Pullamsetti SS, Savai R. IRG1/itaconate rewires macrophage and lung tumor metabolism through G6PD inhibition. Cell Metabolism. 38(7):1460-1477.e8

In 2020, FDA approved the combination of nivolumab (Opdivo) and ipilimumab (Yervoy) for people with unresectable pleural mesothelioma who have not received other treatments.

2026 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)